Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62%
NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.
